ConcertAI appoints Dr. Shaalan Beg as chief medical officer, oncology. Dr. Shaalan Beg ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the appointment of Dr. Shaalan Beg as ConcertAI's chief medical officer, oncology. In his new role, Dr. Beg will lead efforts to grow and engage the CancerLinQ community, ensuring the voices of practicing oncologists and their evolving patient needs are translated into actionable product development insights and innovations across the broader ConcertAI portfolio. In his role as chief medical officer, oncology, Dr. Beg will serve as a trusted liaison between practicing oncologists and ConcertAI. He'll organize and lead advisory boards, working groups and clinician user forums to foster engagement, feedback and shared learning with development teams across ConcertAI's portfolio. Within ConcertAI's own teams, Dr. Beg will use his experience as a practicing oncologist to provide subject matter expertise on oncology workflows, clinical decision-making and real-world data usage to help optimize oncology-focused tools and features. "Dr. Beg's extensive experience working with the American Society of Clinical Oncology and real-world data platforms positions him uniquely to further strengthen our clinical partnerships and help shape our strategy as we continue to scale," said Eron Kelly, CEO of ConcertAI. "As a strategic connector between the CancerLinQ oncologist community and our internal software and product teams, he'll be crucial in ensuring that clinical insights and patient-centered innovation remain at the heart of our technology solutions." Dr. Beg is a nationally recognized medical oncologist and healthcare leader with deep expertise in gastrointestinal cancers, clinical research and oncology informatics. He has served as Senior Advisor for Clinical Research at the National Cancer Institute, where he contributed to national initiatives in trial modernization, public-private partnerships and digital health. His career spans academia, government and industry, including leadership roles at UT Southwestern Medical Center and Science37. Dr. Beg's work has been published in leading journals, including The New England Journal of Medicine, JAMA Oncology and Journal of Clinical Oncology. He has also served as an advisor to the Bloomberg International Cancer Coalition, the White House Cancer Moonshot, CancerX, Coalition for Healthcare AI and ACCC community oncology research institute. Finally, his volunteer work has earned him the designation of Fellow of the American Society of Clinical Oncology. "Having spent my career translating innovation into meaningful clinical impact, I'm looking forward to joining ConcertAI to ensure artificial intelligence can continue improving cancer care and clinical research," said Dr. Beg. "As a practicing oncologist, I'm acutely aware of the challenges faced by life science organizations in developing novel treatments, diagnostics and devices in addition to the needs of healthcare practitioners, and I'm excited to put this knowledge into action with the rest of the ConcertAI team." About ConcertAI ConcertAI is the leader in predictive and generative Al SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai(TM) technologies and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers and medical societies. TeraRecon provides AV, AI and image viewing solutions for medical imaging, including 3D post-processing tools used in radiology, cardiology, neurology and oncology. CancerLinQ(R) is an initiative of ConcertAI, providing oncology providers with ASCOaligned automated QOPI and ASCO Certified(R) quality solutions and SmartLinQ(TM) analytic services. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham and Tokyo. For more information, visit us at concertai.com.

Dr. Oakland joins DNAnexus from ConcertAI, where he served as Vice President and Product Lead for precision oncology solutions, helping deliver AI-powered SaaS and real-world data solutions to pharmaceutical and diagnostic organizations.

ConcertAI, a leader in oncology-focused generative and agentic AI solutions, announced the launch of its new Precision Suite.